Nitto Denko (6988) · InitiativeAdvanced
Expansion of indications for a transdermal patch formulation for hypertension
First written in FY2019-Q3. 1 of 2 entries say "Advanced", first in FY2019. Latest entry: FY2019.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Expanding Sales of Priority PharmaceuticalsA theme 10 companies write about · 0 as a headwind · 12 as a tailwind
3 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2019AdvancedAnnual report
「The transdermal patch formulation developed for hypertension will also be indicated for tachycardic atrial fibrillation.」
The transdermal patch formulation developed for hypertension received an additional indication for tachycardic atrial fibrillation. - FY2019-Q3First statedAnnual report
「The transdermal patch formulation developed for hypertension in collaboration with a customer will also be indicated for tachycardic atrial fibrillation.」
The transdermal patch formulation for hypertension developed in collaboration with a customer received an additional indication for tachycardic atrial fibrillation.